Management of Interstitial Lung Diseases
Introduction
- Interstitial lung disease (ILD) has a prevalence of 25-74 per 100,000 population, with higher incidence in men (31.5 per 100,000) than women (26.1 per 100,000), accounting for approximately 15% of patients seen by pulmonologists, according to the American Thoracic Society 1
Diagnosis and Classification
- High-Resolution CT (HRCT) is the gold standard for confirming ILD diagnosis, with a sensitivity of ~91% and specificity of 71%, and pattern recognition is crucial (UIP, NSIP, HP patterns) 2, 3
- Pulmonary Function Tests (PFTs) show a restrictive pattern (reduced FVC, normal FEV1/FVC ratio) and reduced DLCO, with baseline and follow-up measurements essential to assess progression 4
- Bronchoalveolar Lavage (BAL) is useful for specific ILD patterns, including lymphocytosis, neutrophilia, and eosinophilia, and can help diagnose granulomatous disease, HP, and eosinophilic pneumonia, according to the American Thoracic Society 4, 3
- Lung Biopsy, including Surgical Lung Biopsy (SLB) and Transbronchial Lung Cryobiopsy (TBLC), is recommended for patients with HRCT patterns of probable UIP, indeterminate for UIP, or alternative diagnosis, and can help confirm diagnosis and guide treatment, as suggested by the American Thoracic Society 2, 5
- The American Thoracic Society/European Respiratory Society recommends classifying ILDs based on disease behavior rather than rigid histopathological patterns, with treatment strategies tailored to the specific ILD subtype including bronchiolocentric interstitial pneumonia and diffuse alveolar damage 6
Disease Behavior Classification
- The American Thoracic Society/European Respiratory Society classifies ILDs into five disease behavior categories: reversible and self-limited disease, reversible disease with risk of progression, stable with residual disease, progressive, irreversible disease with potential for stabilization, and progressive, irreversible disease despite therapy 6
Treatment Approach
- For reversible and self-limited disease, treatment involves removing the causative agent, with short-term observation to confirm regression 6
- For reversible disease with risk of progression, initial therapy aims to achieve response, then rationalize long-term treatment, with short-term observation to confirm treatment response and long-term observation to ensure maintained improvement 6
- For progressive, irreversible disease despite therapy, therapies aim to slow progression, with long-term observation to assess disease course and need for transplant or palliation 6
- The American College of Rheumatology recommends glucocorticoids combined with immunosuppressive agents as first-line treatment for CTD-ILD except systemic sclerosis 7
- The American College of Rheumatology strongly recommends against glucocorticoids as first-line treatment for Systemic Sclerosis-ILD (SSc-ILD) 7, 8
- The American College of Rheumatology conditionally recommends mycophenolate mofetil, nintedanib, and tocilizumab as first-line options for SSc-ILD 7, 8
- The American College of Rheumatology conditionally recommends JAK inhibitors and calcineurin inhibitors (tacrolimus preferred over cyclosporine) as first-line options for Inflammatory Myopathy-ILD (IIM-ILD) 7, 8
Management of Specific ILD Subtypes
- For bronchiolocentric fibroinflammatory changes, management involves identifying and removing potential causative agents, considering treatment similar to hypersensitivity pneumonitis if exposure history is present, and monitoring with HRCT and PFTs 6, 9
- For rapidly progressive ILDs, management involves high-dose corticosteroids, consideration of immunosuppressants for refractory cases, and supportive care including oxygen therapy for hypoxemia 10
- For SSc-ILD, nintedanib is conditionally recommended as a first-line option 8
- For SSc-ILD, tocilizumab is a conditionally recommended alternative 8
- For IIM-ILD, JAK inhibitors are conditionally recommended 8
- For IIM-ILD, calcineurin inhibitors (cyclosporine, tacrolimus) are conditionally recommended 8
- Intravenous immunoglobulin (IVIG) is an add-on option for progressive IIM-ILD, particularly useful when rapid onset of action is desired, and beneficial in cases with concurrent respiratory muscle weakness 7
Monitoring and Follow-up
- The European League Against Rheumatism recommends short-term PFTs (within 3 months) and HRCT (within 6 months) to determine progression rate 11
- The European League Against Rheumatism recommends regular monitoring with PFTs every 3-6 months for moderate-to-severe ILD and every 6 months for mild ILD (FVC ≥70% and <20% fibrosis on HRCT) 11
- Progression is defined as a decline in FVC ≥10% predicted, decline in FVC 5-10% with worsening symptoms or increased fibrosis on HRCT, or worsening symptoms with increased fibrosis 8
- A 5% decline in FVC over 12 months is associated with doubled mortality, highlighting the importance of close monitoring 7
Symptomatic Relief and Palliative Care
- The American College of Chest Physicians recommends gabapentin and multimodality speech pathology therapy for refractory cough, and low-dose opiates may be considered for symptomatic relief in palliative settings 12
- Metered dose inhalers are preferred for patients with adequate technique, and nebulizers should be reserved for patients who cannot use inhalers properly, as recommended by the British Thoracic Society 13
- The British Thoracic Society recommends Long-Term Oxygen Therapy (LTOT) for patients with interstitial lung disease (ILD) and resting oxygen levels ≤7.3 kPa 14
- LTOT should be considered for ILD patients with oxygen levels ≤8 kPa if peripheral edema or pulmonary hypertension is present, according to the British Thoracic Society 14
- Portable oxygen therapy should be considered for ILD patients with severe breathlessness, as suggested by the British Thoracic Society 14
Multidisciplinary Approach and Referral
- A multidisciplinary approach involving pulmonologists, rheumatologists, radiologists, and pathologists is crucial for optimal management, as recommended by the European League Against Rheumatism 11
- The American College of Rheumatology recommends early referral for lung transplantation for patients with progressive ILD despite optimal medical management 7
- Early referral for lung transplantation should be considered for patients with progressive ILD, according to the American College of Rheumatology 8
Prevention of Complications
- Pneumocystis jirovecii pneumonia prophylaxis with trimethoprim-sulfamethoxazole is recommended for patients on high-dose corticosteroids, according to the American College of Rheumatology and the Mayo Clinic Proceedings 7, 15
- Calcium and vitamin D supplementation, and consideration of bisphosphonates if osteoporosis is present, are recommended to prevent osteoporosis, as stated by the Mayo Clinic Proceedings 15
- Vaccination (influenza, pneumococcus, COVID-19) is recommended, as stated by the American College of Rheumatology 7